Anti-inflammatory Agents and MonoHER Protect Against DOX-induced Cardiotoxicity and Accumulation of CML in Mice

Overview

Journal Br J Cancer

Specialty Oncology

Date 2007 Feb 28

PMID 17325706

Citations 13

Authors

A M E Bruynzeel

M A Abou El Hassan

C Schalkwijk

J Berkhof

A Bast

H W M Niessen

W J F van der Vijgh

Affiliations

Soon will be listed here.

Abstract

Cardiac damage is the major limiting factor for the clinical use of doxorubicin (DOX). Preclinical studies indicate that inflammatory effects may be involved in DOX-induced cardiotoxicity. Nepsilon-(carboxymethyl) lysine (CML) is suggested to be generated subsequent to oxidative stress, including inflammation. Therefore, the aim of this study was to investigate whether CML increased in the heart after DOX and whether anti-inflammatory agents reduced this effect in addition to their possible protection on DOX-induced cardiotoxicity. These effects were compared with those of the potential cardioprotector 7-monohydroxyethylrutoside (monoHER).BALB/c mice were treated with saline, DOX alone or DOX preceded by ketoprofen (KP), dexamethasone (DEX) or monoHER. Cardiac damage was evaluated according to Billingham. Nepsilon-(carboxymethyl) lysine was quantified immunohistochemically. Compared to saline, a 21.6-fold increase of damaged cardiomyocytes was observed in mice treated with DOX (P<0.001). Addition of KP, DEX or monoHER before DOX significantly reduced the mean ratio of abnormal cardiomyocytes in comparison to mice treated with DOX alone (P<or=0.02). In addition, DOX induced a significant increase in the number of CML-stained intramyocardial vessels per mm2 (P=0.001) and also in the intensity of CML staining (P=0.001) compared with the saline-treated group. Nepsilon-(carboxymethyl) lysine positivity was significantly reduced (P<or=0.01) by DOX-DEX, DOX-KP and DOX-monoHER. These results confirm that inflammation plays a role in DOX-induced cardiotoxicity, which is strengthened by the observed DOX-induced accumulation of CML, which can be reduced by anti-inflammatory agents and monoHER.

Citing Articles

Exploring the Anticancer Potential of MonoHER (7-Mono-O-(β-Hydroxyethyl)-Rutoside): Mitochondrial-Dependent Apoptosis in HepG2 Cells.

Li C, Wang Y, Liang J, Haenen G, Chen Y, Li Z Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852151 PMC: 11763755. DOI: 10.3390/cimb47010036.

Inflammation in Chemotherapy-Induced Cardiotoxicity.

Hutchins E, Yang E, Stein-Merlob A Curr Cardiol Rep. 2024; 26(12):1329-1340.

PMID: 39377963 PMC: 11668833. DOI: 10.1007/s11886-024-02131-5.

Choline Protects the Heart from Doxorubicin-Induced Cardiotoxicity through Vagal Activation and Nrf2/HO-1 Pathway.

Guo F, Wang Y, Wang J, Liu Z, Lai Y, Zhou Z Oxid Med Cell Longev. 2022; 2022:4740931.

PMID: 35422894 PMC: 9005275. DOI: 10.1155/2022/4740931.

Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients.

Wu L, Baylan U, van der Leeden B, Schurink B, Roos E, Schalkwijk C Int J Cardiol. 2021; 349:157-165.

PMID: 34871622 PMC: 8641429. DOI: 10.1016/j.ijcard.2021.11.079.

Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy.

Lodi M, Priksz D, Fulop G, Bodi B, Gyongyosi A, Nagy L J Transl Med. 2019; 17(1):229.

PMID: 31324258 PMC: 6642576. DOI: 10.1186/s12967-019-1978-0.

References

Gharib M, Burnett A . Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail. 2002; 4(3):235-42. DOI: 10.1016/s1388-9842(01)00201-x. View

Bruynzeel A, Mul P, Berkhof J, Bast A, Niessen H, van der Vijgh W . The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice. Cancer Chemother Pharmacol. 2006; 58(5):699-702. DOI: 10.1007/s00280-006-0206-9. View

Kataoka M, Tonooka K, Ando T, Imai K, Aimoto T . Hydroxyl radical scavenging activity of nonsteroidal anti-inflammatory drugs. Free Radic Res. 1998; 27(4):419-27. DOI: 10.3109/10715769709065781. View

Van Acker S, Boven E, Kuiper K, Van Den Berg D, Grimbergen J, Kramer K . Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res. 1998; 3(10):1747-54. View

Nerlich A, Schleicher E . N(epsilon)-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Atherosclerosis. 1999; 144(1):41-7. DOI: 10.1016/s0021-9150(99)00038-6. View

Kang B, Kim S, Cho D, Kim T . Inhibition of interleukin-12 production in mouse macrophages via decreased nuclear factor-kappaB DNA binding activity by myricetin, a naturally occurring flavonoid. Arch Pharm Res. 2005; 28(3):274-9. DOI: 10.1007/BF02977791. View

van der Vijgh W, Maessen P, Pinedo H . Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. Cancer Chemother Pharmacol. 1990; 26(1):9-12. DOI: 10.1007/BF02940286. View

Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A . Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986; 232(4758):1629-32. DOI: 10.1126/science.3487117. View

Von Hoff D, Layard M, Basa P, Davis Jr H, Von Hoff A, Rozencweig M . Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91(5):710-7. DOI: 10.7326/0003-4819-91-5-710. View

10.

Fadillioglu E, Oztas E, Erdogan H, Yagmurca M, Sogut S, Ucar M . Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. J Appl Toxicol. 2004; 24(1):47-52. DOI: 10.1002/jat.945. View

11.

Nagai R, Ikeda K, Higashi T, Sano H, Jinnouchi Y, Araki T . Hydroxyl radical mediates N epsilon-(carboxymethyl)lysine formation from Amadori product. Biochem Biophys Res Commun. 1997; 234(1):167-72. DOI: 10.1006/bbrc.1997.6608. View

12.

Deepa P, Varalakshmi P . Influence of a low-molecular-weight heparin derivative on the nitric oxide levels and apoptotic DNA damage in adriamycin-induced cardiac and renal toxicity. Toxicology. 2005; 217(2-3):176-83. DOI: 10.1016/j.tox.2005.09.009. View

13.

Yamada K, Nakamura T, Utsumi H . Enhanced intraarticular free radical reactions in adjuvant arthritis rats. Free Radic Res. 2006; 40(5):455-60. DOI: 10.1080/10715760500440536. View

14.

Dunn J, Patrick J, Thorpe S, Baynes J . Oxidation of glycated proteins: age-dependent accumulation of N epsilon-(carboxymethyl)lysine in lens proteins. Biochemistry. 1989; 28(24):9464-8. DOI: 10.1021/bi00450a033. View

15.

Hou G, Dick R, Abrams G, Brewer G . Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med. 2005; 146(5):299-303. DOI: 10.1016/j.lab.2005.07.004. View

16.

van Acker F, Van Acker S, Kramer K, Haenen G, Bast A, van der Vijgh W . 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clin Cancer Res. 2000; 6(4):1337-41. View

17.

Schalkwijk C, Baidoshvili A, Stehouwer C, van Hinsbergh V, Niessen H . Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim Biophys Acta. 2004; 1636(2-3):82-9. DOI: 10.1016/j.bbalip.2003.07.002. View

18.

Scheinman R, Cogswell P, Lofquist A, Baldwin Jr A . Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995; 270(5234):283-6. DOI: 10.1126/science.270.5234.283. View

19.

Schleicher E, Wagner E, Nerlich A . Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997; 99(3):457-68. PMC: 507819. DOI: 10.1172/JCI119180. View

20.

Chen Q, Alexander D, Sun H, Xie L, Lin Y, Terrand J . Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: induction of antiapoptosis, antioxidant, and detoxification genes. Mol Pharmacol. 2005; 67(6):1861-73. DOI: 10.1124/mol.104.003814. View